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ABSTRACT (250 words; words used = 249) 
Purpose: To investigate improvements in overactive bladder (OAB) and patient-reported 
outcomes in refractory incontinent OAB patients treated with mirabegron 50 mg plus 
solifenacin 5 mg vs solifenacin 5 or 10 mg. 
Materials and Methods: Incontinent OAB patients, despite 4-weeks single-blind daily 
solifenacin 5 mg, were randomized 1:1:1 to double-blind, daily combination (mirabegron 50 
mg/solifenacin 5 mg), solifenacin 5 or 10 mg for 12 weeks. Mirabegron dose was increased 
from 25 mg to 50 mg after week 4. Symptom Bother, health-related quality of life (HRQoL), 
and patient perception of bladder condition (PPBC) were assessed using respective OAB-q 
and PPBC questionnaires; responder rates were based on 50% reduction in daily 
incontinence, zero incontinence episodes and <8 micturitions/24 hours, and minimal 
important differences in OAB-q and PPBC. 
Results:  Overall 2,174 patients, median age 59 years, were randomized to combination 
(n=727), solifenacin 5 mg (n=728) or 10 mg (n=719). Symptom Bother, total HRQoL and its 
subscales (Coping, Concern, and Social) and PPBC were significantly improved with 
combination vs solifenacin monotherapy (P<0.05). The odds of achieving clinically 
meaningful improvements in incontinence and micturition frequency, Symptom Bother, 
HRQoL and PPBC, was significantly higher with combination vs solifenacin monotherapy. 
The odds (95% CI) of becoming continent was 47% (OR 1.47; 1.17, 1.84; p=0.001) and 28% 
(OR 1.28; 1.02, 1.61; p=0.033) higher with combination vs solifenacin 5 and 10 mg, 
respectively.  
Conclusion: Significantly more patients on combination achieved clinically meaningful 
improvements in incontinence and micturition frequency, which were accompanied by 
similar improvements in PPBC, Symptom Bother and HRQoL.  
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Overactive bladder (OAB) is defined by symptoms of urinary urgency, usually accompanied 
by increased daytime frequency and nocturia, with or without urgency incontinence, in the 
absence of urinary tract infection or other obvious pathology.1,2 Urgency urinary 
incontinence affects approximately one third of all OAB cases.3 Compared with continent 
(“dry”) OAB patients, incontinent (“wet”) OAB patients experience greatly diminished 
quality of life (QoL), reporting higher rates of depression, psychological and emotional 
distress, and social isolation.4,5 The severity of urgency urinary incontinence is strongly 
correlated with reductions in QoL,6 suggesting that incontinent OAB patients who are 
refractory to treatment are likely to be extremely dissatisfied with their QoL. Daily activities 
are often severely disrupted, and incontinent patients are more likely to require assistance 
with daily activities, placing an additional financial burden on society.7 OAB patients are 
more likely to seek treatment once symptoms affect health-related quality of life (HRQoL),8 
and  to persist with treatment if HRQoL improves.9 
Objective efficacy assessments are essential in OAB trials. However, the greatest 
treatment benefit experienced by patients is likely to be related to improvements in QoL. It 
is, therefore, equally important to assess subjective, patient-reported outcomes (PROs) 
including HRQoL and perception of symptoms, and how these correlate with clinically 
meaningful improvements in OAB symptoms. Bladder health questionnaires such as the 
overactive bladder questionnaire (OAB-q) assess overall HRQoL, symptom bother and 
domains related to daily activities, social functioning and sleep. Understanding the impact of 
OAB symptoms and their treatment from the perspective of the patient, in addition to 
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clinically relevant improvements in symptoms based on the micturition diary, will improve 
treatment satisfaction and the effective management of OAB symptoms. 
Antimuscarinics (eg solifenacin) and the β3-adrenoceptor agonist, mirabegron, are the 
oral pharmacotherapies for treating OAB. Both classes of drugs exhibit similar efficacy, but 
unlike antimuscarinics, mirabegron is not associated with anticholinergic side effects.10–12 
Patients are usually initiated on an antimuscarinic, with dose escalation if symptom 
improvement is inadequate. This may increase the anticholinergic burden, the risk of 
bothersome side effects and treatment discontinuation.13 Other patients may be switched 
to an alternative antimuscarinic or mirabegron. Those who do not meet their treatment goal 
with medical therapy are potential candidates for intravesical onabotulinumtoxinA, an 
invasive treatment that may require intermittent self-catheterization  and is often 
characterized by a fluctuating response over time, and urinary tract infection.14 Other 
alternatives include percutaneous tibial nerve stimulation and sacral nerve stimulation.15, 16  
The BESIDE study (NCT01908829) demonstrated a significant benefit with 12 weeks’ 
solifenacin 5 mg plus add-on mirabegron in incontinent OAB patients vs solifenacin 5 and 10 
mg monotherapy in terms of improving daily incontinence, micturition frequency and 
urgency. Furthermore, the safety profile of the combination was similar to that of 
mirabegron or solifenacin monotherapy.17 
This analysis assessed whether improvements in objective endpoints translated into 
improvements in subjective HRQoL endpoints. PROs were investigated using bladder health 
questionnaires to evaluate HRQoL, treatment satisfaction and each patient’s perception of 
their bladder condition. In addition, responder analyses assessed the proportion of patients 
who achieved clinically meaningful improvements in incontinence (asymptomatic [“dry”] or 
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≥50% reduction in incontinence episodes) and micturition frequency (<8 micturitions/24 
hours) at the end of treatment (EoT). The objectives were to compare combination 
(solifenacin 5 mg/mirabegron 50 mg) with solifenacin 5 and 10 mg in terms of PROs related 
to HRQoL, and to explore the relationship between clinically relevant improvements in PROs 
and in micturition frequency and incontinence. 
 
METHODS 
Study Design and Patient Demographics 
In this randomized, double-blind, parallel-group, multicenter phase IIIb study, patients ≥18 
years of age, with OAB for ≥3 months, including an average of ≥2 incontinence episodes/24 
hours entered a 2-week screening/wash-out period to remove the effects of previous OAB 
medication and familiarize with the patient-recorded electronic micturition diary. After 4 
weeks of single-blind daily solifenacin 5 mg, patients remaining incontinent (≥1 episode 
during the 3-day diary) at baseline, were eligible for double-blind treatment (Fig. 1). 
Patients who satisfied inclusion and did not meet exclusion criteria (Appendix A1) 
were randomized 1:1:1 to 12 weeks of double-blind daily treatment with combination 
(solifenacin 5 mg plus mirabegron 25 mg for first 4 weeks, increasing to mirabegron 50 mg 
for the remaining 8 weeks), solifenacin 5 or 10 mg (Appendix A2). 
 
Patient-reported Outcomes 
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QoL was assessed using the OAB-q (Symptom Bother score, total HRQoL and subscales of 
Coping [toilet mapping], Concern, Sleep and Social Interaction), the patient perception of 
bladder condition (PPBC) questionnaire, and the treatment satisfaction-visual analog scale 
(TS-VAS) (Table 1); the OAB-q and PPBC have been validated in OAB trials.18-20 Questionnaire 
scores were recorded by the patient using an electronic handheld device at baseline, weeks 
4, 8 and 12/EoT. The primary analysis was change from baseline to EoT in scores for 
Symptom Bother, HRQoL and subscales, TS-VAS and PPBC. 
 
Responder Analyses 
Seven responder analyses, 3 based on objective efficacy outcomes for incontinence and 
micturition frequency, and 4 based on PROs related to HRQoL and PPBC, were selected for 
inclusion. Based on the 3-day micturition diary prior to each study visit, efficacy responders 
were defined as patients with ≥50% decrease from baseline in mean number of 
incontinence episodes/24 hours at EoT, zero incontinence episodes at EoT (“dry” OAB 
patients), and ≥8 micturitions/24 hours at baseline and <8 micturitions/24 hours at EoT. 
PRO responders were defined as a patient who achieved a change from baseline to EoT 
that exceeded the minimal important difference (MID) in the OAB-q or PPBC. The MID is 
defined as “the smallest difference in score in the domain of interest that patients perceive 
as beneficial and which would mandate, in the absence of troublesome side effects and 
excessive costs, a change in patient management”,21 and equates to 10 points for the total 
OAB-q and its subscales (HRQoL and Symptom Bother)22-24 and a 1-point improvement in 
PPBC.20 Based on the change from baseline to EoT, PRO responders were those patients 
with: ≥10-point improvement in OAB-q Symptom Bother; ≥10-point improvement in OAB-q 
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total HRQoL score; ≥1-point improvement in PPBC; and a major (≥2-point) improvement in 
PPBC. 
 
Exploratory Variables: Double and Triple Responder Analyses 
Double and triple responder analyses based on a composite of efficacy (≥50% reduction in 
incontinence episodes/24 hours at EoT) and PROs (MIDs achieved in OAB-q [Symptom 
Bother and total HRQoL] and/or PPBC) were investigated as exploratory variables. 
 
Statistical Analysis 
Sample size was based on previous studies with mirabegron and mirabegron/solifenacin 
combination, and mirabegron 50 mg vs placebo results.25-28 A total of 614 patients in each 
treatment group provided 90% power to detect a reduction of 0.50 in the mean number of 
daily micturitions for combination vs solifenacin 5 mg; 610 patients provided 80% power for 
the analysis of mean number of daily incontinence episodes and 90% power to detect a 
reduction of 20% in the number of incontinence episodes during the 3-day diary. Assuming 
15% dropout during the double-bind period, 724 patients were to be randomized to each 
group. 
PROs and responder analyses were assessed in the full analysis set (FAS; randomized 
patients who received ≥1 dose of double-blind medication, with ≥ 1 micturition and 
incontinence episode reported at baseline and ≥1 post baseline micturition). Changes from 
baseline in PPBC, Symptom Bother, HRQoL and subscales and TS-VAS scores were analyzed 
using an analysis of covariance model with treatment and randomization stratification 
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factors and baseline value as covariate. Missing EoT data were imputed using the last 
observation carried forward method. 
For dichotomous variables (eg ≥50% decrease in incontinence episodes), the 
difference in the proportion of responders between combination vs solifenacin 5 or 10 mg, 
odds ratios, 95% confidence intervals (CIs), and p values were calculated from a logistic 
regression model including treatment group, randomization stratification factors (sex, age 
group, geographic region and 4-week incontinence episode reduction group) and baseline 
measurement. 
A similar logistic regression model was used to analyze the proportion of 
double/triple responders, however, the baseline measurement was log-transformed to 
improve model fit. Changes and responders from baseline were only calculated if data from 
baseline and post baseline visits were available (Appendix A3). 
 
RESULTS 
Patient Demographics 
Overall 2,174 patients were randomized to combination (n=727), solifenacin 5 mg (n=728) 
or solifenacin 10 mg (n=719) (Fig. 2). Patient demographics and baseline characteristics 
were similar across groups and included a median age 59.0 years, mean number of 
incontinence episodes/24 hours >3, mean number of micturitions/24 hours >8, and OAB-q 
scores indicative of significantly impaired QoL (Symptom Bother score >50 [scores range 
from 0 to 100; higher scores indicate greater symptom bother] and total HRQoL score ~60 
[scores range from 0 to 100; higher scores indicate better QoL]) (Table 2). 
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Patient-reported Outcomes 
Combination demonstrated superiority over solifenacin 5 and 10 mg for change from 
baseline to EoT in the Symptom Bother score, total HRQoL and subscales (with the 
exception of Sleep vs solifenacin 5 mg) and the PPBC (Fig. 3). The mean adjusted (95% CI) 
difference in the Symptom Bother score was −4.96 (−6.88, −3.04; p<0.001) and −3.30 (−5.23, 
−1.37; p=0.001) for the combination vs solifenacin 5 and 10 mg, respectively. The mean 
(95% CI) adjusted difference in the total HRQoL was 3.15 (1.35, 4.95; p=0.001) and 3.38 
(1.58, 5.19; p <0.001) for the combination vs solifenacin 5 and 10 mg, respectively. The 
change from baseline to EoT in the TS-VAS was statistically significantly higher for 
combination compared with solifenacin 5 mg (Fig. 3D).  
 
Efficacy and PRO Responder Analyses 
At EoT, there were statistically significant differences in favor of combination vs both 
solifenacin 5 and 10 mg for the proportion of responders who became continent, and vs 
solifenacin 5 mg for those with a ≥50% decrease in incontinence episodes/24 hours and 
normalization of micturition frequency (<8 micturitions/24 hours) (Fig. 4A–C). Odds ratios 
for combination treatment vs solifenacin 5 and 10 mg, respectively, indicated that patients 
receiving combination were 47% (OR 1.47; 95% CI 1.17, 1.84; p=0.001) and 28% (OR 1.28; 
95% CI 1.02, 1.61; p=0.033) more likely to achieve zero incontinence, 51% and 25% more 
likely to achieve a ≥50% reduction in incontinence episodes/24 hours and 29% and 12% 
more likely to achieve normalization of micturition frequency. There were statistically 
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significant odds ratios in favor of combination vs solifenacin 5 and 10 mg in the proportion 
of responders with ≥10-point improvement in Symptom Bother score, the total HRQoL and a 
major (≥2 point) improvement in PPBC (Fig. 4D–G). The odds of achieving MIDs in Symptom 
Bother, total HRQoL and a major improvement in PPBC, respectively, was 75%, 50% and 
55% higher with combination vs solifenacin 5 mg, and 54%, 47% and 29% higher vs 
solifenacin 10 mg. 
 
Exploratory Variables: Double and Triple Responder Analyses 
At EoT, statistically significant improvements were demonstrated for all 5 exploratory 
variables in favor of the combination group vs solifenacin 5 mg, and for 3 of the 5 variables 
vs solifenacin 10 mg (Table 3). Compared with solifenacin 5 and 10 mg, respectively, 
patients on combination were 73% and 26% more likely to simultaneously achieve a ≥50% 
reduction in incontinence episodes/24 hours, ≥10-point improvement in Symptom Bother 
score, and ≥1-point improvement in PPBC, and 55% and 39% more likely to achieve this 
triple responder status but with a ≥10-point improvement in total HRQoL rather than 
Symptom Bother. 
 
DISCUSSION 
QoL encompasses socio-demographic, clinical, psychological and social factors highlighting 
the importance of assessing the patients’ perceptions of treatment on their OAB symptoms. 
OAB patients with refractory incontinence are more likely to have a poor QoL and negative 
experience of their treatment than “dry” OAB patients.4,5 Alternative options in patients 
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who do not respond to, or cannot tolerate, antimuscarinic dose escalation may involve 
invasive, intravesical onabotulinumtoxinA or neuromodulation therapies.  
 The validity of the bladder health questionnaires, OAB-q and PPBC, and the clinical 
utility of the respective MIDs have been confirmed in previous studies and demonstrate a 
strong correlation with symptom improvement based on bladder diary assessment.18–20 
Responder analyses in this study identified the proportion of patients achieving clinically 
meaningful improvements in subjective measures of HRQoL and treatment perception, and 
objective efficacy outcomes, individually or combined (double/triple responders). 
In refractory incontinent OAB patients, combination significantly improved Symptom 
Bother, total HRQoL and its subscales vs solifenacin monotherapy, with the exception of the 
HRQoL subscale of “Sleep” vs solifenacin 5 mg. This may be related to the reduced 
treatment effect with combination and solifenacin monotherapy on nocturia, as previously 
reported.17 Similar benefits were observed with combination vs solifenacin 5 mg for 
treatment satisfaction and patients’ perception of major improvements in their condition. 
A higher proportion of patients on combination compared with solifenacin 5 and 10 
mg achieved clinically meaningful improvements in efficacy and PRO responder analyses, 
which was significant in most cases. Compared with solifenacin 5 mg, patients receiving 
combination were approximately 50% more likely to achieve full continence or a ≥50% 
reduction in incontinence. This benefit was less pronounced for micturition normalization, 
which may have been due to low baseline micturition frequency (~9 episodes/24 hours) 
resulting from the initial 4-week solifenacin 5 mg run-in period.  The odds of achieving MIDs 
in the OAB-q (Symptom bother and total HRQoL) and a major improvement in PPBC was ≥ 
50% higher with combination vs solifenacin 5 mg. The responder analyses confirm that OAB 
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patients who achieve significant reductions in symptoms experience significant benefits in 
HRQoL.  
Double and triple responder analyses identified the proportion of patients who 
simultaneously achieved clinically meaningful improvements in incontinence, HRQoL and 
perception of bladder symptoms. The odds of achieving > 50% reduction in incontinence, 
MIDs in the OAB-q (Symptom bother and total HRQoL), and ≥ 1 point improvement in PPBC 
were > 50% higher with combination vs solifenacin 5 mg. The magnitude of improvements 
in QoL and the proportion of responders compares favorably with a post hoc analysis of 
pooled PRO data in phase III studies investigating mirabegron monotherapy and with 
corresponding groups in a dose-ranging phase II study of solifenacin 2.5/5/10 mg plus 
mirabegron 25/50 mg.29, 30 In the primary analysis of the BESIDE study, the adverse event 
profile for the combination was consistent with the known profiles for mirabegron and 
solifenacin with no signal for new adverse events, nor was there any additive/synergistic 
effect on vital signs with combination.17 The significant benefit in symptom resolution and 
positive patient experience in this study suggests that refractory incontinent OAB patients 
may be more likely to benefit with a combination of mirabegron and solifenacin rather than 
persisting with solifenacin 5 mg or dose escalating to solifenacin 10 mg.  
Study limitations included lack of multiplicity adjustment across the PROs and 
responder analyses, increasing the risk of chance findings. Furthermore, like most OAB 
trials, the male population was underrepresented. Despite these limitations, BESIDE clearly 
demonstrated improved outcomes, and is the first study to explore PROs with combination 
therapy in a large population of refractory incontinent OAB patients. Further studies are 
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recommended with a larger male demographic, other antimuscarinics as active comparator, 
and patients with refractory urgency and/or frequency.  
 
CONCLUSIONS 
Compared with solifenacin monotherapy, combination therapy (solifenacin 5 mg and 
mirabegron 50 mg) was associated with clinically significant improvements in incontinence 
and micturition frequency, which were accompanied by clinically meaningful improvements 
in Symptom Bother, HRQoL and PPBC. 
Words = 2502 
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TABLES  
Table 1. Summary of characteristics of bladder health questionnaires  
Assessment 
Tool 
Items Scoring System Clinical Relevance 
OAB-q Self-reported questionnaire 
comprising 33-items each rated 
on a 6-point Likert scale 
Consists of an 8-item Symptom 
Bother scale and 25 HRQoL 
items comprising 4 HRQoL 
subscales (Coping, Concern, 
Sleep and Social Interaction) 
Scores are transformed onto a 0 
to 100 scale 
Higher scores in HRQoL indicate 
better QoL (positive change 
indicates improvement) 
Lower scores on the Symptom 
Bother scale indicate a better 
QoL (negative change indicates 
improvement) 
HRQoL scores are directly related to patient wellbeing; 
a 10-point improvement is recognized as a minimally 
important difference 
Symptom Bother scale is directly related to the degree 
of patient discomfort (bother) with the symptoms of 
OAB; a 10-point improvement is recognized as a 
minimally important difference24 
Validated in clinical and community settings and has 
demonstrated reliable internal consistency, test-retest 
BESIDE Responder 3rd draft February 2016 
21 
 
reliability, construct validity and responsiveness among 
patients with a range of OAB symptoms18,19, 23 
PPBC One item questionnaire using a 
6-point Likert scale, ranging 
from 1 “My bladder does not 
cause me any problems at all” 
to 6 “My bladder condition 
causes me many severe 
problems” 
Lower scores and negative 
change indicates improvement 
in bladder condition 
 
Indicates subjective impression of patient’s current 
bladder condition 
A 1-point and 2-point (major) improvement in PPBC are 
minimal important differences 
Offers a broad assessment of patient response that 
incorporates multiple elements of the disease in a 
simple question and has also demonstrated test-retest 
reliability, construct validity and responsiveness to 
change20 
TS-VAS Treatment Satisfaction Visual 
Analog Scale 
Scale from 0 (No, not at all) to 10 
(Yes, completely) 
TS-VAS rates patient satisfaction with treatment 
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HRQoL, health-related quality of life, OAB-q, overactive bladder questionnaire, PPBC, patient perception of bladder condition, TS-VAS, 
treatment satisfaction-visual analog scale.  
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Table 2. Summary of demographics, baseline characteristics and OAB-related baseline characteristics (FAS) 
 Combination 
N=707 
Solifenacin 5 mg 
N=705 
Solifenacin 10 mg 
N=698 
Sex, n (%) 
  Female 
  Male  
 
588 (83.2) 
119 (16.8) 
 
584 (82.8) 
121 (17.2) 
 
585 (83.8) 
113 (16.2) 
Race, n (%) 
  White 
  Black/African American 
  Asian 
  Other 
 
671 (94.9) 
19 (2.7) 
13 (1.8) 
4 (0.6) 
 
656 (93.0) 
24 (3.4) 
21 (3.0) 
4 (0.6) 
 
661 (94.7) 
26 (3.7) 
9 (1.3) 
2 (0.3) 
Mean age (SD) 
  ≥65 years, n (%) 
  ≥75 years, n (%) 
58.0 (13.2) 
223 (31.5) 
71 (10.0) 
56.9 (13.4) 
214 (30.4) 
64 (9.1) 
57.3 (13.2) 
214 (30.7) 
53 (7.6) 
BMI (kg/m2)    
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Mean (SD) 29.0 (5.9) 29.1 (6.3) 29.0 (6.0) 
Mean duration of OAB, months, (SD) 75.8 (86.2) 
 
67.8 (71.6) 
 
70.1 (77.1) 
 
Previous OAB medication (prior to 
screening), n (%) 
474 (67.0) 
 
487 (69.1) 
 
479 (68.6) 
 
Number of previous OAB medications, n (%) 
  0 
  1 
  2 
  >2 
 
233 (33.0%) 
266 (37.6%) 
114 (16.1%) 
94 (13.3%) 
 
218 (30.9%) 
268 (38.0%) 
129 (18.3%) 
90 (12.8%) 
 
219 (31.4%) 
259 (37.1%) 
116 (16.6%) 
104 (14.9%) 
Previous OAB medication discontinued for 
[1] [2], n (%): 
  Insufficient effect 
  Poor tolerability 
 
 
423 (89.2%) 
89 (18.8%) 
 
 
428 (87.9%) 
96 (19.7%) 
 
 
417 (87.1%) 
106 (22.1%) 
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Previous solifenacin treatment (prior to 
screening), n (%) 
269 (38.0%) 297 (42.1%) 281 (40.3%) 
Previous mirabegron treatment (prior to 
screening), n (%) 
43 (6.1%) 39 (5.5%) 41 (5.9%) 
Number of incontinence episodes during 3-
day diary, mean (SD) 
9.6 (8.9)  
 
9.4 (8.1) 
 
9.9 (9.1) 
 
Incontinence episodes/24 hours, mean (SD) 3.23 (3.00) 3.16 (2.73) 3.31 (3.05) 
Micturitions/24 hours, mean (SD) 9.12 (2.79)  8.90 (2.72) 8.96 (2.75) 
TS-VAS, mean (SE) [n] 6.0 (0.1) [693] 6.0 (0.1) [683] 6.1 (0.1) [675] 
PPBC, mean (SE) [n] 4.3 (0.0) [697] 4.2 (0.0) [688] 4.2 (0.0) [683] 
OAB-q Symptom Bother score, mean (SE) 
[n] 
53.51 ( 0.76) [694] 51.85 ( 0.78) [683] 52.63 ( 0.78) [676] 
OAB-q total HRQoL, mean (SE) [n] 58.83 (0.85) [694] 59.32 (0.89) [683] 60.14 (0.87) [676] 
HRQoL subscale Coping, mean (SE) [n] 52.26 (0.98) [694] 53.44 (1.01) [683] 54.09 (1.00) [676] 
HRQoL subscale Concern, mean (SE) [n] 58.47 (0.95) [694] 58.73 (0.99) [683] 59.75 (0.97) [676] 
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HRQoL subscale Sleep, mean (SE) [n] 55.29 (0.93) [694] 56.00 ( 0.94) [683] 55.85 (0.94) [676] 
HRQoL subscale Social, mean (SE) [n] 73.39 (0.92) [694] 72.90 (0.95) [683] 74.67 (0.91) [676] 
BMI, body mass index, HRQoL, health-related quality of life, OAB, overactive bladder, OAB-q, overactive bladder questionnaire, PPBC, patient 
perception of bladder condition, SD, standard deviation. TS-VAS, treatment satisfaction-visual analog scale 
The full analysis set (FAS) included all randomized patients who took at least 1 dose of double-blind study drug after randomization, reported 
at least 1 micturition and at least 1 incontinence episode in the baseline diary and at least 1 micturition post baseline. 
[1] Only patients who used previous OAB medications 
[2] Patients could have discontinued previous OAB medications for several reasons 
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Table 3. Double responder analyses at EoT: 50% reduction in mean number of incontinence episodes/24 hours and improvement ≥10 points 
on the Symptom Bother Scale (OAB-q); 50% reduction in mean number of incontinence episodes/24 hours and ≥ 10-point improvement on 
HRQoL Total score (OAB-q); 50% reduction in mean number of incontinence episodes/24 hours and ≥ 1-point improvement in PPBC; and triple 
responder analyses at EoT: 50% reduction in mean number of incontinence episodes/24 hours, improvement by ≥10 points on the Symptom 
Bother Scale (OAB-q) and ≥1-point improvement in PPBC; 50% reduction in mean number of incontinence episodes/24 hours, improvement by 
≥10 points on the HRQoL Total Score (OAB-q) and ≥1-point improvement in PPBC. 
 Combination 
(n=707) 
Solifenacin 5 mg 
(n=705) 
 
Solifenacin 10 mg 
(n=698) 
Double responders at EoT 
50% reduction in incontinence and MID (≥10-point improvement) achieved on Symptom Bother score (OAB-q) 
Responders, n (%) 432 (62.2) [n=694] 342 (50.1) [n=683] 382 (56.5) [n=676] 
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Difference vs solifenacin 5 mg 
(95% CI) 
12.17 (6.97 to 17.38)  
Odds ratio vs solifenacin 5 mg 
(95% CI) 
1.66 (1.33 to 2.07) 
p <0.001 
 
Difference vs solifenacin 10 mg 
(95% CI) 
5.74 (0.55 to 10.93)  
Odds ratio vs solifenacin 10 mg 
(95% CI) 
1.25 (1.00 to 1.56) 
p = 0.050 
 
50% reduction in incontinence and MID (≥10-point improvement) achieved on total HRQoL score (OAB-q) 
Responders, n (%) 371 (53.5) [n=694] 294 (43.0) [n=683] 301 (44.5) [n=676] 
Difference vs solifenacin 5 mg 
(95% CI) 
10.41 (5.16 to 15.66)  
Odds ratio vs solifenacin 5 mg 
(95% CI) 
1.59 (1.27 to 2.00) 
p <0.001 
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Difference vs solifenacin 10 mg 
(95% CI) 
8.93 (3.66 to 14.20)  
Odds ratio vs solifenacin 10 mg 
(95% CI) 
1.41 (1.13 to 1.77) 
p = 0.003 
 
50% reduction in incontinence and ≥1-point improvement in PPBC 
Responders, n (%) 407 (58.4) [n=697] 337 (49.0) [n=688] 363 (53.1) [n=683] 
Difference vs solifenacin 5 mg 
(95% CI) 
9.41 (4.18 to 14.64)  
Odds ratio vs solifenacin 5 mg 
(95% CI) 
1.49 (1.20 to 1.86) 
p <0.001 
 
Difference vs solifenacin 10 mg 
(95% CI) 
5.25 (0.01 to 10.48)  
Odds ratio vs solifenacin 10 mg 
(95% CI) 
1.22 (0.97 to 1.52) 
p = 0.083 
 
Triple responders: change from baseline to EoT 
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50% reduction in incontinence, MID (≥10-point improvement) achieved on Symptom Bother score (OAB-q), ≥1-point improvement in PPBC 
Responders, n (%) 385 (55.5) [n=694] 288 (42.2) [n=683] 332 (49.1) [n=676] 
Difference vs solifenacin 5 mg 
(95% CI) 
13.31 (8.08 to 18.54)  
Odds ratio vs solifenacin 5 mg 
(95% CI) 
1.73 (1.39 to 2.16) 
p <0.001 
 
Difference vs solifenacin 10 mg 
(95% CI) 
6.36 (1.08 to 11.64)  
Odds ratio vs solifenacin 10 mg 
(95% CI) 
1.26 (1.01 to 1.58) 
p = 0.037 
 
50% reduction in incontinence, MID (≥10-point improvement) achieved on total HRQoL score (OAB-q), ≥1-point improvement in PPBC 
Responders, n (%) 333 (48.0) [n=694] 260 (38.1) [n=683] 267 (39.5) [n=676] 
 
Difference vs solifenacin 5 mg 
(95% CI) 
9.92 (4.71 to 15.12)  
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Odds ratio vs solifenacin 5 mg 
(95% CI) 
1.55 (1.23 to 1.94) 
p <0.001 
 
Difference vs solifenacin 10 mg 
(95% CI) 
8.49 (3.25 to 13.72)  
Odds ratio vs solifenacin 10 mg 
(95% CI) 
1.39 (1.10 to 1.74) 
p = 0.005 
 
CI, confidence interval, EoT, end of treatment, HRQoL, health-related quality of life, MID, minimal important difference, OAB-q, overactive 
bladder questionnaire, PPBC, patient perception of bladder condition.  
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Figure Legends 
Figure 1. Study design.17 
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Figure 2. Patient disposition.17 
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Figure 3. The adjusted mean change from baseline to EoT in patient-reported outcomes and treatment differences (95% CI and p value) vs 
solifenacin 5 mg and 10 mg. A, Total HRQoL, B, Symptom Bother score, C, HRQoL subscales (Concern, Coping, Sleep, Social), D, TS-VAS, E, PPBC. 
A. 
 
 
 
B. 
 
C. CONCERN C. COPING 
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D.
 
E.  
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Figure 4. Proportion of responders at EoT with: A, ≥50% decrease from baseline in mean number of incontinence episodes/24 hours, B, zero 
incontinence episodes/24 hours, C, mean of ≥8 micturitions/24 hours at baseline and <8 micturitions/24 hours, D, ≥10-point improvements 
from baseline in OAB-q Symptom Bother score, E, ≥10-point improvements from baseline in HRQoL Total score, F, ≥1-point improvement in 
PPBC, G, ≥2-point improvement in PPBC. 
A.  
 
 
 
B.  
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APPENDIX A (online supplementary) 
A1. Key Inclusion and Exclusion Criteria 
A2. Randomization and Blinding 
A3. Sample Size Calculation and Statistical Analysis 
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Supplementary materials 
A1. Key Inclusion and Exclusion Criteria 
Inclusion Exclusion 
Screening (Visit 1) 
Adult with OAB symptoms for ≥3 months 
Patient has symptoms of “wet” OAB 
(frequency and urgency with 
incontinence or mixed incontinence with 
predominant urgency incontinence) 
 
Clinically significant Bladder Outlet Obstruction 
(BOO) 
Significant PVR volume (PVR >150 ml) 
Significant stress incontinence or mixed 
stress/urgency incontinence where stress is the 
predominant factor 
Intravesical treatment in past 12 months 
Non-drug treatment including sacral nerve 
stimulation therapy (a bladder training program 
or pelvic floor exercises which began more than 
30 days prior to study entry can be continued) 
 
Run-in (Visit 2) 
During the 3-day micturition diary, patient 
experiences on average: 
≥1 episode of urgency (grade 3 or 4)/24 
hours with or without incontinence 
≥2 incontinence episodes/24 hours 
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≥8 micturitions/24 hours (excluding 
incontinence episodes)  
 
Randomization (Visit 3) 
Patient experiences ≥1 incontinence 
episode during the 3-day micturition 
diary period and wishes to increase their 
treatment for OAB symptoms 
 
Patient has achieved 100% continence from 
Visit 2 to Visit 3 (no incontinence episodes are 
recorded in the 3-day diary administered for  
3 days prior to Visit 3) 
Patient does not desire an increase in study 
medication 
Patient has an average total daily urine volume 
>3,000 ml as recorded in the micturition diary 
Severe uncontrolled hypertension (sitting 
average SBP ≥180 mmHg and/or DBP ≥110 
mmHg) 
Clinically significant abnormal ECG 
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A2. Randomization and Blinding 
Each patient number was assigned using interactive response technology once the patient 
had signed informed consent. Patients were randomized to 1 of 3 treatment groups in a 
1:1:1 ratio stratified by sex, age group (<65, ≥65 years), 4-week incontinence episode 
reduction group (<50%, ≥50%), and geographic region (ie Eastern Europe, Western Europe, 
North America, Middle East and Asia). 
To maintain blinding for the double-blind treatment period, active and placebo 
tablets were indistinguishable by using a double-dummy packaging system. Neither patient 
nor other study personnel were aware of the double-blind treatment given to any patient 
unless a medical emergency necessitated such disclosure. For the single-blinded run-in 
period, all patients received 1 active tablet of solifenacin 5 mg. For the single-blinded safety 
follow-up period, 1 placebo tablet was given. 
For the first 4 weeks of the double-blind period, patients were assigned to 1 of 3 groups: 
 Combination: solifenacin 5 mg, mirabegron 25 mg, solifenacin 10 mg placebo 
 Solifenacin 5 mg: solifenacin 5 mg, mirabegron 25 mg placebo, solifenacin 10 mg 
placebo 
 Solifenacin 10 mg: solifenacin 5 mg placebo, mirabegron 25 mg placebo, solifenacin 
10 mg 
For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron and 
matching placebo were replaced by a 50 mg mirabegron tablet and matching placebo tablet. 
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A3. Sample Size and Statistical Analysis 
The sample size for this study was based on results of previous studies with mirabegron and 
solifenacin plus mirabegron combination25 and mirabegron 50 mg vs placebo results.26-28 
A total of 614 evaluable patients per treatment group provided 90% power to detect 
a reduction of 0.50 in the mean number of micturitions/24 hours for combination therapy vs 
solifenacin 5 mg monotherapy at a 2-sided significance level of 0.05, assuming a standard 
deviation of 2.7. A total of 610 patients provided 80% power for the analysis of mean 
number of incontinence episodes per 24 hours based on a (non-parametric) Wilcoxon rank 
sum test based on ordered categories derived from the results of the previous studies 
mentioned above. A total of 610 evaluable patients per treatment group provided 90% 
power to detect a reduction in the number of incontinence episodes reported during the  
3-day diary period for combination therapy vs solifenacin 5 mg monotherapy of at least 20% 
at a 2-sided significance level of 0.05. This sample size was based on an analysis of Poisson 
regression, using an over-dispersion factor of 2.75 and an expected number of 4 
incontinence episodes over a 3-day diary period for the solifenacin 5 mg monotherapy arm 
at EoT. Assuming a 15% dropout rate during the double-bind period, 724 patients were to 
be randomized to each arm. Using data from previous solifenacin studies it was assumed 
that 25% of incontinent patients would be continent after receiving 4 weeks of solifenacin  
5 mg. Based on this rate of 25%, a total of approximately 2,896 patients were planned to 
enter the single-blind treatment period. Assuming a 15% screening failure rate, 
approximately 3,408 patients were to be screened in countries across Europe, North 
America, Middle East, North Africa and Asia Pacific to achieve approximately 2,172 
randomized and 1,842 evaluable patients. 
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Demographic and other baseline characteristics were summarized using descriptive 
statistics for the continuous variables and numbers and percentages of patients for the 
categorical variables. 
For dichotomous variables (eg proportion of patients with at least a 50% decrease in 
incontinence episodes, at least a 1-point improvement in PPBC), the number and proportion 
of responders were summarized by treatment group, along with the difference between 
combination therapy and solifenacin 5 mg and between combination therapy and 
solifenacin 10 mg, odds ratios, 95% CIs, and p values. These were calculated from a logistic 
regression model including treatment group, randomization stratification factors (sex, age 
group, geographic region and 4-week incontinence episode reduction group) and baseline 
measurement. Patients with missing outcome leading to missing response status were 
excluded. 
The proportions of double and triple responders were summarized by treatment 
group, along with the difference between combination therapy and solifenacin 5 mg and 
between combination therapy and solifenacin 10 mg, odds ratios, 2-sided 95% CIs and p 
values. These were calculated from a logistic regression model including treatment group, 
randomization stratification factors (sex, age group (<65 and ≥65 years), geographic region 
and 4-week incontinence episode reduction group) and log transformation of the baseline 
measurement. Descriptive statistics for the exploratory variables at each study visit and EoT 
as well as the model statistics were tabulated by treatment group. 
Changes and responders from baseline to weeks 4, 8 and 12 were only calculated if 
data from both baseline visit and the post baseline visit were available. Missing EoT data 
were imputed using the LOCF method. Patients with completely missing data were not 
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included in the analysis (so that the number of responders plus the number of 
nonresponders corresponded to the number of patients included in the by-week analyses). 
 
 
